A stock-market overview built around the names that matter most in the public conversation today: Novo Nordisk (NVO), Eli Lilly (LLY), Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), Altimmune (ALT), Fractyl Health (GUTS) and Zealand Pharma (ZEAL). This first part is not a medical explainer. It is a market map: who already has real commercial power, who is still trying to earn strategic relevance, and which catalysts actually matter for the shares.